Dr. Rahul Gupta

Thanks for having me, Scott. It's great to be on your program. I have just completed a stint in the federal government on the dealing with the opioid crisis. So this has been where You know, when I got in in 2021, the president said in the White House that, hey, here's a problem that's not been solved ever.

Thanks for having me, Scott. It's great to be on your program. I have just completed a stint in the federal government on the dealing with the opioid crisis. So this has been where You know, when I got in in 2021, the president said in the White House that, hey, here's a problem that's not been solved ever.

We've got a 31 percent increasing drug overdose deaths that were going over about 100,000 people dying, Americans across the country. And I need you to fix it. So just like in business, in government, you kind of have to go back and look at your plan and either revise it, fix it, or get out. So we started a plan, put together what we know now fast forward about four years.

We've got a 31 percent increasing drug overdose deaths that were going over about 100,000 people dying, Americans across the country. And I need you to fix it. So just like in business, in government, you kind of have to go back and look at your plan and either revise it, fix it, or get out. So we started a plan, put together what we know now fast forward about four years.

we're now seeing about 24% declines in those deaths. So 31% incline, 24% decline, that's a turnaround of 55%. Never has happened in the history of the United States. And we're saving a lot of lives. And it's a combination of getting more treatment out there, life-saving medications, as well as helping people survive, but also thrive in their lives while addressing the trafficking problem as well.

we're now seeing about 24% declines in those deaths. So 31% incline, 24% decline, that's a turnaround of 55%. Never has happened in the history of the United States. And we're saving a lot of lives. And it's a combination of getting more treatment out there, life-saving medications, as well as helping people survive, but also thrive in their lives while addressing the trafficking problem as well.

Certainly, Scott. One of the things that I found a little bit not up to par in my previous position was, hey, we're not focusing as much on drug discovery.

Certainly, Scott. One of the things that I found a little bit not up to par in my previous position was, hey, we're not focusing as much on drug discovery.

We're not focusing as much because primarily having new medications while people are dying on the streets from things like not just opioids and cocaine, but also from things like PTSD, post-traumatic stress disorder, as well as Parkinson's and dementia and diabetes. We don't have a lot of pipeline of drugs. So the question then became for me personally as a trained physician, why is that?

We're not focusing as much because primarily having new medications while people are dying on the streets from things like not just opioids and cocaine, but also from things like PTSD, post-traumatic stress disorder, as well as Parkinson's and dementia and diabetes. We don't have a lot of pipeline of drugs. So the question then became for me personally as a trained physician, why is that?

And what I saw was that the industry, it's very risky. Drug development is inherently a risky business with more than 90% failure rate in the initial preclinical phases. It's also costly. because it costs over a billion dollars to get a drug out there in the market. And lastly, I'll say it's very slow. It takes between 10 and 15 years to get a product out there.

And what I saw was that the industry, it's very risky. Drug development is inherently a risky business with more than 90% failure rate in the initial preclinical phases. It's also costly. because it costs over a billion dollars to get a drug out there in the market. And lastly, I'll say it's very slow. It takes between 10 and 15 years to get a product out there.

So my interest became, how can I help accelerate these processes into having Less risk, less cost, and rapid discovery. And that's what drove me to the market leader in this area, which is GATC Health, where I'm able to work towards a solution in a time where we can help people live longer at a lower cost and get those drugs in the pipeline faster through technology.

So my interest became, how can I help accelerate these processes into having Less risk, less cost, and rapid discovery. And that's what drove me to the market leader in this area, which is GATC Health, where I'm able to work towards a solution in a time where we can help people live longer at a lower cost and get those drugs in the pipeline faster through technology.

Well, it's going to be 15 on a scale of 1 to 10. I'll tell you why. Because this is literally what I consider science fiction as a scientist come into real life.

Well, it's going to be 15 on a scale of 1 to 10. I'll tell you why. Because this is literally what I consider science fiction as a scientist come into real life.

I mean, I'm dealing with an area, an arena at the right time where artificial intelligence and machine learning is helping us now have those drug targets identified early, the model for drug design developed through deep learning models, as well as getting these predictive analysis where we have predictions of greater than 80% success.

I mean, I'm dealing with an area, an arena at the right time where artificial intelligence and machine learning is helping us now have those drug targets identified early, the model for drug design developed through deep learning models, as well as getting these predictive analysis where we have predictions of greater than 80% success.

So we don't have to put these molecules through years and years of funding, but also studies while people are dying on the street. So it gives me immense pleasure to see that I can help contribute to lowering the cost, increasing the speed at which these medications get out there, and to help people. So I'm absolutely excited about it.

So we don't have to put these molecules through years and years of funding, but also studies while people are dying on the street. So it gives me immense pleasure to see that I can help contribute to lowering the cost, increasing the speed at which these medications get out there, and to help people. So I'm absolutely excited about it.